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Abstract
Background: Small intestine neuroendocrine tumors (SI-NETs) belong to a rare group of cancers. Most patients have
developed metastatic disease at the time of diagnosis, for which there is currently no cure. The delay in diagnosis is a major
issue in the clinical management of the patients and new markers are urgently needed. We have previously identified
paraneoplastic antigen Ma2 (PNMA2) as a novel SI-NET tissue biomarker. Therefore, we evaluated whether Ma2
autoantibodies detection in the blood stream is useful for the clinical diagnosis and recurrence of SI-NETs.
Methodology/Principal Findings: A novel indirect ELISA was set up to detect Ma2 autoantibodies in blood samples of
patients with SI-NET at different stages of disease. The analysis was extended to include typical and atypical lung carcinoids
(TLC and ALC), to evaluate whether Ma2 autoantibodies in the blood stream become a general biomarker for NETs. In total,
124 blood samples of SI-NET patients at different stages of disease were included in the study. The novel Ma2 autoantibody
ELISA showed high sensitivity, specificity and accuracy with ROC curve analysis underlying an area between 0.734 and 0.816.
Ma2 autoantibodies in the blood from SI-NET patients were verified by western blot and sequential immunoprecipitation.
Serum antibodies of patients stain Ma2 in the tumor tissue and neurons. We observed that SI-NET patients expressing Ma2
autoantibody levels below the cutoff had a longer progression and recurrence-free survival compared to those with higher
titer. We also detected higher levels of Ma2 autoantibodies in blood samples from TLC and ALC patients than from healthy
controls, as previously shown in small cell lung carcinoma samples.
Conclusion: Here we show that high Ma2 autoantibody titer in the blood of SI-NET patients is a sensitive and specific
biomarker, superior to chromogranin A (CgA) for the risk of recurrence after radical operation of these tumors.
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Introduction
Gastrointestinal neuroendocrine tumors (GI-NETs) by tradition
are known as carcinoids and they are rare tumors. They arise from
enterochromaffin cells, which are sparse neuroendocrine cells
disseminated throughout the GI tract [1,2,3]. GI-NETs comprise
well-differentiated NET (benign carcinoid), well-differentiated
neuroendocrine carcinoma (malignant carcinoids) and poorly
differentiated neuroendocrine carcinoma [4]. GI-NETs include
small intestine neuroendocrine tumors (SI-NETs), which have
been called midgut carcinoids [5]. NETs are life-threatening
diseases that have been the subject of investigation for more than a
century. They derive from cells that have the unique ability to
synthesize, store and secrete a variety of metabolic active products
peptides, and amines, which cause specific clinical syndromes in
different parts of the body [3,6]. Lung NETs comprise 20% of all
lung cancers and represent a spectrum of tumors differentiating
from neuroendocrine cells of the respiratory tract. They are
managerially separated into four subgroups on the basis of clinical
characteristics: typical carcinoid tumor (TC), atypical carcinoid
tumor (AC), large-cell neuroendocrine carcinoma (LCNEC), and
small-cell lung carcinoma (SCLC) [7,8].
Most GI and lung NET patients have developed metastatic
disease at the time of diagnosis and surgery is seldom curative
[2,9]. Surgical debulking and hepatic embolization are not
curative per se and conventional chemo-radiotherapy has little or
no effects. The current treatments of metastasized GI and lung
NETs aim at controlling tumor growth and hormonal secretion by
using mainly somatostatin analogs and interferon alfa [10]. The
slow progress in the development of novel curative treatments is
partly due to a lack of tumor biology knowledge, late diagnosis,
and a lack of novel biomarkers for early tumor detection and
PLoS ONE | www.plosone.org 1 December 2010 | Volume 5 | Issue 12 | e16010recurrence [11]. Today the best-characterized circulating bio-
marker that identifies NETs in general is chromogranin A (CgA)
which belongs to the granin family. The family counts eight
members [6]. Furthermore, CgA had been considered the first
important circulating biomarker to evaluate recurrence in
radically operated midgut carcinoid tumors [12] which, herein
are classified as SI-NETs.
We have recently identified six novel marker genes for
neuroendocrine tumor cells by using Affymetrix microarrays
analysis [13]. We profiled normal small intestine mucosa, primary
tumors and liver metastasis using advanced bioinformatics analysis
to identify differentially and specifically expressed genes. One of
the novel marker genes found was PNMA2. These results have
been deposited on NCBI’s GEO (accession number: GSE9576)
and EBI’s Array-Express database (accession number: E-TABM-
389) [13]. Human PNMA2 encodes the paraneoplastic antigen
Ma2 which belongs to the human PNMA family [14]. Paraneo-
plastic antigens, which are normally expressed only in neuronal
tissues, can in the process of carcinogenesis be detected in tumors
located outside the nervous system. The term paraneoplastic
syndrome (PNS) refers to a pathology caused by tumor cells, which
systematically produce a large amount of hormones, growth
factors, cytokines and a variety of specific symptoms [15,16].
PNS may affect any part of the nervous system and muscles.
Immunoresponses to cancer, which cross-react with self-antigens
in the nervous system or muscle lead to production of
onconeuronal antibodies detection [16,17]. Despite the efforts to
elucidate the effects of such antibodies on neurons, only a few
onconeuronal antibodies have been identified as primary effectors
of neurological symptoms. PNS is uncommon and defined by an
acute or sub-acute neurological syndrome associated with a
cancer. Examples of PNS are sub-acute cerebellar ataxia, limbic
encephalomyelitis, Lambert-Eaton myasthenic syndrome, derma-
topolymyositis and intestinal pseudo- obstruction [15]. The
symptoms of PNS often appear before the diagnosis of malignant
cancer and probable cases of PNS may suggest early antitumor
therapy and immunotherapy to prevent progressive neuronal
death. Symptoms can be also caused by neuroendocrine cells that
are present in the GI tract and in the lung [2]. However,
understanding whether the antibodies are associated with specific
neurological symptoms or are only marker of anticancer immune
reaction is difficult [16].
The functions of the proteins encoded by PNMA genes are not
clear. However, MOAP1/PNMA4 was identified as a Bax-
associating protein inducing apoptosis in mammalian cells. The
significant homology of MOAP1/PNMA4 and the other PNMA
proteins suggested a potential role in apoptosis for PNMA proteins
[18,19]. Antitumor immune responses to neuronal antigens
expressed by tumor cells may lead to detectable levels of antibodies
in serum and plasma [14,15,16].
Voltz et al. identified anti-Ma2 antibodies in patients suffering
from testicular cancer and paraneoplastic limbic or brain-stem
encephalitis or both [20]. The antibodies are often present in sera
from patients suffering from neurological PNS [15,21,22].
Scientific evidence has shown that anti-Ma2 positive sera
sometimes are associated with tumor diagnosis [15,16,23,24].
The finding that Ma2 is expressed in primary SI-NETs and
metastases [13] prompted us to screen whether Ma2 autoanti-
bodies are detectable in blood of NET patients to establish
potential novel biomarkers and to evaluate their clinical
implications in tumor diagnosis and prognosis. In this study, we
set up a novel indirect enzyme-linked immunosorbent assay
(ELISA) to detect Ma2 autoantibodies in blood samples of 124 SI-
NET patients at different stages of disease. We also extended the
evaluation to lung carcinoid patients’ blood to verify that our assay
is able to detect the presence of Ma2 autoantibodies in different
neuroendocrine tumors. SI-NETs and lung carcinoids originate
from cells, which synthesize and secrete biologically active
compounds that are able to produce either humoral PNS or less
commonly neurological PNS. The clinicians at the Uppsala
University Hospital and the European Institute of Oncology have
never identified PNS or neurological symptoms in the patients we
used in our study.
To our knowledge this is the first study that shows that Ma2
autoantibodies is a biomarker with diagnostic and prognostic
relevance in the blood stream of SI-NET patients. Ma2
autoantibodies evaluation can identify recurrence of SI-NET
patients with higher precision than measurements of plasma CgA
levels. This novel finding can significantly improve the clinical
management of SI-NET patients.
Results
Indirect ELISA detects Ma2 autoantibodies in primary SI-
NET patients
Significantly higher Ma2 autoantibody titer in SI-NET patients
compared to healthy volunteers were detected by using the novel
indirect ELISA. The reproducibility of the assay is expressed in
intra- and inter-assay percent coefficient of variation (CV) as
explained in Material & Methods. The difference was clear both
considering the diverse categories of malignancies, primary
tumors, lymph node and liver metastasis (Figure 1A), and the
whole SI-NETs cohort of patients (Figure 1B). The sensitivity of
the ELISA is from 46% to 50%. The specificity threshold is 98%
as described in Material and Methods. Receiving operating
characteristic (ROC) curve analyses were used to evaluate the
possible use of Ma2 autoantibodies as early blood marker for SI-
NET. ROC analyses show areas under the curves (AUCs) from
0.734 to 0.816 indicating good accuracy as a diagnostic test.
Figure 1C, 1D and 1E show the results of healthy controls (HC)
versus (vs.) SI-NET primary tumors (P), vs. SI-NET lymph node
metastases (LNM) and vs. SI-NET liver metastases (LM). Figure 1F
shows the results of HC vs. SI-NET patients as a whole, for all
stages of disease. The results are summarized in the upper part of
Table 1.
Detection of Ma2 autoantibodies in sera from HC and
primary SI-NET patients
The ELISA results inspired us to further characterize the
presence and specificity of autoantibodies to Ma2 in serum of SI-
NET patients with primary tumor. The presence was verified by
using western blot analysis and the specificity by using sequential
immunoprecipitation. We loaded purified GST-tagged PNMA2
recombinant protein on SDS-PAGE and blotted the gel. The
Western blot membrane was immunoblotted either with commer-
cial antibodies or serum samples. We confirmed that our
commercial goat antibody specifically detects Ma2 antigen (Figure
S1). To confirm the purity of GST-tagged PNMA2 recombinant
protein anti-GST- and anti-PNMA2 antibodies were used as
controls (Figure 2A, lanes I and II). Sera from healthy controls
exhibit minimum titer of Ma2 autoantibodies, determined by the
indirect ELISA and shown by the low recognition of GST-tagged
PNMA2 recombinant protein (lanes III and IV). Primary SI-NET
patients, with low titer of Ma2 autoantibodies, determined by the
indirect ELISA, showed low recognition of GST-tagged PNMA2
recombinant protein (lanes V and VI), whereas SI-NET patients
with high frequency of Ma2 autoantibodies showed high
Ma2 Autoantibodies and Carcinoids
PLoS ONE | www.plosone.org 2 December 2010 | Volume 5 | Issue 12 | e16010Figure 1. A novel indirect ELISA detects Ma2 autoantibodies in serum from SI-NET patients. Healthy controls (HC), untreated SI-NET
patients with primary tumor (P), lymph node metastasis (LNM) and liver metastasis (LM) were evaluated for the presence of Ma2 autoantibodies.
Horizontal bars in bold indicate the medians in each group. Horizontal lines indicate the cutoff at 1.96 SD above the mean of anti-Ma2 concentration
of HC. Significant differences, which are shown by p values, were detected between HC and each stage of malignancy (A) and between HC and all the
SI-NET patients (B). ROC analyses and AUCs results are shown in C, D, E and F. The highlighted points in each graph indicate the cutoff.
doi:10.1371/journal.pone.0016010.g001
Table 1. Results of indirect ELISA assay for Ma2 autoantibodies.
Group Type
Anti-Ma2 Median
(Range) (AU) Sensitivity (n) Specificity (n) AUC (95% CI, p- value)
Healthy Controls 1079 (433–2100) 98.0% (49/50)
SI-NETs Primary Tumor 1844 (579–6782) 47.2% (17/36) 2 0.816 (0.720–0.912, p,0.0001)
Lymph Node Metastasis 1868 (391–4499) 50.0% (19/38) 2 0.802 (0.702–0.903, p,0.0001)
Liver Metastasis 1712 (424–7890) 46.0% (23/50) 2 0.734 (0.633–0.835, p,0.0001)
Total SI-NET 1804 (391–7890) 47.6% (59/124) 2 0.779 (0.712–0.846, p,0.0001)
Lung Carcinoids TLC 1456 (570–6891) 30.8% (16/52) 2 0.693 (0.591–0.795, p=0.0008)
ALC 2013 (515–3506) 50.0% (7/14) 2 0.766 (0.592–0.939, p=0.0025)
Total Lung Carcinoids 1494 (515–6891) 34.8% (23/66) 2 0.709 (0.616–0.801, p=0.0001)
doi:10.1371/journal.pone.0016010.t001
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shows the semiquantitative measurement of band densities.
Next we confirmed the specificity of Ma2-specific autoantibod-
ies in serum samples from the patients by sequential immunopre-
cipitation using
35S-methionine-labeled human Ma2 protein
generated by in vitro transcription-coupled translation as described
in Material and Methods. Ma2-specific autoantibodies were
detected in serum samples from primary SI-NET patients
expressing high titer of Ma2 autoantibodies (Figure 2B, lanes 6,
7, and 8) but not in serum samples from healthy controls (lanes 3,
4, and 5). Lane 1 shows immune precipitation with a commercial
goat anti-human PNMA2 (positive control) and lane 2 shows
immunoprecipitation without antibody or serum (negative con-
trol). The lower panel of Figure 2B shows the result of autora-
diography of the blot. Recently, we showed that serum antibodies
of patients detect Ma2 and faintly Ma1 by using commercial
immuno-dot-blot (Figure S1).
Progression free survival (PFS) and recurrence free
survival (RFS) of primary SI-NET patients, after surgery
with curative intent, depend on Ma2 autoantibody titer
We have evaluated the clinical data of 36 patients followed up
after radical operation of primary tumors with a curative intent.
We evaluated Kaplan-Meyer survival curves, followed by a log-
rank test to determine whether the curves were different. The
hazard ratios were calculated, based on Cox regression function as
described in Material and Methods, and found to be 4.31
(p-value=0.011) for progression free survival (PFS) and 4.24
(p-value=0.012) for recurrence free survival (RFS). The analysis
showed that 19 patients with Ma2 autoantibody titer below the
cutoff had a longer PFS compared to 17 patients with Ma2
autoantibody titer higher than the cutoff, Figure 3A. The same
was true for patients with RFS, Figure 3B. The significance of the
analyses is clearly expressed by both p-values=0.006. The median
survival time for each group of patients was estimated from the
survival curves. It was clearly shorter for patients with Ma2
autoantibody titer higher than the cutoff with an estimated time of
about 40 months compared to those with levels below the cutoff
with an estimated survival time of about 125 months. The results
are summarized in Table 2. Clinical information for patients with
Ma2 autoantibodies concentration , cutoff are to the left in
Table 2 and clinical information for patients with Ma2
autoantibodies concentration . cutoff are to the right.
Circulating CgA is considered important in indicating tumor
recurrence in most radically operated midgut carcinoid tumor
patients. Therefore, we wanted to evaluate the significance of CgA
protein expression levels on PFS and RFS in our patient material.
The median level of circulating CgA in 36 patients with primary
tumors was mainly within the same reference range with CgA
,4.0 ng/ml, as shown in Table 2. The Cox regression modeling
as explained in Material and Methods revealed that anti-Ma2 titer
is more predictive of patient outcome than CgA concentration.
The statistical analysis of PFS showed that Cox proportional
hazard for the progression time in function of anti-Ma2 + CgA
properly fits; p value=0.0192. Clear effect of anti-Ma2 titer was
found (coefficient=0.000409 and p-value=0.013), whereas no
significant effect of CgA was found (coefficient=0.141492,
p-value=0.087). Similar analysis of RFS showed that Cox
proportional hazard for the recurrence time in function of anti-
Ma2 + CgA fits with p-value=0.0222. Clear effect of anti-Ma2
titer was shown (coefficient=0.000397, p-value=0.015); whereas
no significant effect of CgA was found (coefficient=0.140190,
p-value=0.089). We observed that in the group of 19 patients with
Ma2 autoantibody titer , cutoff only 4 patients had tumor
recurrence during the follow-up. 2 of these 4 patients had
increased CgA levels. Furthermore, in the group of 17 patients
with Ma2 autoantibody titer . cutoff 13 patients presented tumor
recurrence. CgA levels increased in only one out of these 13
patients. Our study clearly shows by Cox modeling that CgA is not
predictive of PFS and RFS.
Circulating Ma2 autoantibody levels and Ma2 expression
in SI-NET patients
Matched blood samples and formalin-fixed paraffin-embedded
tumor material from 20 untreated SI-NET patients at different
stage of disease with primary tumors (P), lymph node metastasis
Figure 2. Detection of Ma2 autoantibodies in serum of healthy
controls and primary SI-NET patients. 2A) GST-tagged fusion
PNMA2 recombinant protein was subjected to SDS-PAGE followed by
Western blotting analysis. A mouse anti-GST antibody (lane I) and a
goat anti-PNMA2 antibody (lane II) verified the GST-tagged PNMA2
recombinant protein. Lanes III-IV, sera from 2 healthy donors; Lanes V-VI
sera from 2 primary SI-NET patients with low anti-Ma2 titer; Lanes VII-
VIII, sera from 2 primary SI-NET patients with high anti-Ma2 titer. Lanes
III to VIII show differences in the amount of Ma2 autoantibodies. The
lower panel shows the semiquantitative measurement of band
densities of the blot. 2B) autoradiographic image of sequentially
immunoprecipitated
35S-Met-Ma2, positive control (lane 1); negative
control (lane 2); sera from 3 healthy donors with low anti-Ma2 titer
(lanes 3–5); sera from 3 primary SI-NET patients with high anti-Ma2 titer
(lanes 6–8). The lower panel shows the semiquantitative measurement
of pixel densities of the autoradiographic image.
doi:10.1371/journal.pone.0016010.g002
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PLoS ONE | www.plosone.org 4 December 2010 | Volume 5 | Issue 12 | e16010Figure 3. PFS and RFS of primary SI-NET patients after surgery with curative intent depend on Ma2 autoantibody titer. Patients were
divided in two groups based on the Ma2 autoantibody titer either below or above the cutoff at 1900 AU as described in Material and Methods.
Kaplan-Meier survival curve analyses were plotted for PFS (A) and RFS (B). The p-values of the differences between the two groups were obtained by
using the log-rank test for each evaluation.
doi:10.1371/journal.pone.0016010.g003
Table 2. Ma2 autoantibody levels and associated clinical characteristics of primary SI-NET patients analyzed after surgery with a
curative intent.
Anti-Ma2 Concentration , cutoff Anti-Ma2 Concentration . cutoff
Age/
Gender
Anti-Ma2
(AU)
CgA
(ng/ml)
Follow-up
(month)
PFS
(month)
Recurrence
(month)
Age/
Gender
Anti-Ma2
(AU)
CgA
(ng/ml)
Follow-up
(month)
PFS
(month)
Recurrence
(month)
47/M 915 3.7 63 63 43/M 6785 2.6 42 24 25
77/M 1091 2.6 163 163 37/F 4402 2.9 132 132
67/F 1686 6.4 146 122 126 35/M 3200 2.4 62 62
76/M 887 4.2 96 84 87 70/M 2548 2.8 144 96 99
64/M 1645 2.1 38 38 70/F 4758 3.4 96 48 51
59/M 1596 8.9 6 4 4 75/M 5064 3.0 102 61 64
52/F 1148 5.5 23 23 53/M 3982 3.3 80 12 15
50/F 1445 3.5 15 15 54/M 2547 2.6 19 14 17
68/M 1404 4.7 12 12 47/M 2553 3.8 91 42 44
38/M 1582 2.9 18 18 54/F 3794 3.5 44 34 35
70/M 1058 2.6 16 16 75/F 2456 9.2 12 12
62/M 579 1.8 87 87 30/F 3005 13.6 52 37 40
71/M 1255 3.2 78 54 62 76/M 3260 4.3 38 38
69/M 1814 2.2 77 77 67/M 2152 1.8 49 27 30
48/F 1736 3.3 49 49 67/M 3581 1.6 61 43 45
67/M 964 1.9 48 48 71/M 4640 4.5 75 30 32
78/M 1835 3.7 26 26 62/M 3612 2.1 43 32 34
82/M 862 3.7 18 18
76/F 1852 2.5 74 74
Median
67 1404 3.3 48 48 74.5 62 3581 3.0 62 37 35
Mean
64.3 1334.4 3.7 55.4 52.2 69.8 58 3667 4.0 70.7 43.8 40.8
doi:10.1371/journal.pone.0016010.t002
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correlation between the serum titer of Ma2 autoantibodies and the
tumor expression of Ma2 antigen. Patients are described in Table
S1. We evaluated serum samples by ELISA and the expression of
Ma2 by immunohistochemistry (IHC) analysis. The ELISA results
found that 12 patients out of 20 expressed Ma2 autoantibodies
with titer higher than the cutoff, whereas 8 patients out of 20
expressed Ma2 autoantibodies with titer lower than the cutoff. The
results are summarized in Table S1. We confirmed that our
commercial rabbit antibody specifically detects Ma2 antigen
(Figure S1) Ma2 immunohistochemistry was then performed on
primary tumors and metastases from the same patients. The results
showed that all 12 patients who expressed Ma2 autoantibodies
with titer higher than the cutoff were positive for Ma2 in the
tumors. Moreover, 7 out of 8 patients who expressed Ma2
autoantibodies with titer lower than the cutoff were positively
stained as well. Therefore, we conclude that there is no evident
correlation between the Ma2 autoantibody titer and the amount of
Ma2 expression. Immunohistochemical Ma2 staining of the tumor
specimens are summarized in Table S1. Positively stained tissues
showed PNMA2 immunoreactivity from faint to moderate
granular accumulation of immunostaining product confined to
the cytoplasm of most tumor cells. Stromal cells were completely
negative verifying Ma2 immunoreaction specificity. Figure S2A
shows four representative stainings from patients with high titer of
Ma2 autoantibodies and Figure S2B shows four representative
stainings from patients with low titer of Ma2 autoantibodies.
Patient serum is able to recognize Ma-2 and Ma-1 as shown in
Figure S1. Immunohistochemistry analysis was also performed on
paraffin sections from patients suffering from SI-NET primary
tumors and liver metastases by using serum from patients with
high titer of Ma2 autoantibodies and serum from healthy controls
with low titer of Ma2 autoantibodies. The Auerbach’s plexus,
which is part of the enteric nervous system, is located between the
longitudinal and circular layers of muscularis externa in the
gastrointestinal tract and provides motor innervation. Serum from
healthy controls faintly stained the tumor cells and the neurons
whereas serum patients with high titer of Ma2 autoantibodies
clearly detected Ma2 in the neuroendocrine tumor cells and
neurons of the Auerbach’s plexus (or myenteric plexus). Repre-
sentative immunohistochemical Ma2 staining of tumor cells and
neurons is shown in Figure S3.
Novel indirect ELISA detects Ma2 autoantibodies in lung
carcinoids
Previous results on small cell lung carcinoma samples suggested
analyzing the presence of Ma2 antigen in typical and atypical lung
carcinoid tissue. Immunohistochemistry analysis on paraffin
sections showed increased expression of Ma2 in comparison with
normal internal tissues. The mean of Ma2-positive tumor cells in
typical carcinoids is 54% and in atypical carcinoids is 28%,
independent of tumor growth patterns of the former, Figure S4.
We next explored whether lung carcinoid tumors were associated
with anti-Ma2 antibodies. The 66 blood samples from lung
carcinoids patients (52 typical and 14 atypical) were compared to
50 samples from healthy volunteers. The samples were first
analyzed as 2 groups according to the TC and AC classification
and named TLC and ALC, Figure 4A. The two different groups
are significantly distinguished from healthy controls as shown by
the p-values. Lung carcinoids were also considered as a whole and
the results show that the group of patients is clearly distinguished
from healthy controls as indicated by p-value in Figure 4B. The
sensitivity, specificity and AUCs of ROC analysis in lung carcinoid
patients are presented in the lower part of Table 1. ROC curve
analysis evaluated the possible use of Ma2 autoantibodies as
potential early blood marker for lung carcinoids. ROC analyses
were used to study healthy controls vs. TLC as shown in Figure 4C,
healthy controls vs. ALC as shown in Figure 4D, and healthy
controls vs. both typical and atypical lung carcinoids, as shown in
Figure 4E. The AUCs are between 0.693 and 0.766, indicating
fair accuracy as a diagnostic test.
Discussion
We have recently profiled primary SI-NETs and liver
metastases by using Affymetrix microarrays and identified that
paraneoplastic antigen Ma2 is produced by enterochromaffin cells
and neuroendocrine tumor cells [13]. Few studies have correlated
paraneoplastic syndrome to patients with midgut carcinoids and
lung carcinoids as well [15,25]. Our finding that Ma2 was
consistently detected in primary SI-NET specimens and in a
variety of metastasis made it interesting to investigate whether
antibodies against Ma2 are present in the blood of SI-NET
patients.
The main purpose of the present study was to assess whether
Ma2 autoantibodies can be used as a specific and sensitive blood-
based marker for a more accurate diagnosis and progression of SI-
NETs. We set up a novel indirect ELISA able to accurately screen
the Ma2 autoantibody levels in serum or plasma samples. We
confirmed the specificity of serum Ma2 autoantibodies by using
western blot and sequential immunoprecipitation analyses. A
central aspect of our investigation is that Ma2 autoantibodies
discriminate a large portion of SI-NET patients from healthy
controls both considering the diverse tumor categories which
reflect different stages of disease and as a whole. The evaluation of
the different levels of Ma2 autoantibodies, which were detectable
in the diverse categories of patients, is reliable considering the high
values of sensitivity, specificity and AUC values from the ROC
analyses. The AUC values are convincing to continue to screen
more samples as new SI-NET patients are being diagnosed. This
would imply that Ma2 autoantibodies are likely produced early in
the development of SI-NETs, with maintenance of steady blood
levels during tumor progression.
One of the most important clinical problems is to detect early
disease as well as to detect early recurrence after surgery with a
curative intent. Increased CgA levels in blood is the standard
biomarker and considered important in indicating tumor recur-
rence in most radically operated midgut carcinoid tumor patients
[12,26]. We had the possibility to follow 36 patients with primary
tumors operated with a curative intent. We found that the median
level of CgA is within the reference range, ,4 ng/ml in both
groups of patients below and above cutoff level for Ma2
autoantibodies i.e. that CgA levels are not indicative in this group
of patients. We observed that in the group of patients with Ma2
autoantibodies below cutoff level, 4 patients out of 19 recurred
within a median of 74 months, whereas in the group of patients
with Ma2 autoantibodies above cutoff level, 13 patients out of 17
recurred within a median of 35 months. Therefore, in this case the
ELISA that detect Ma2 autoantibodies can reliably identify about
47% of the SI-NET patients at the primary stage of the disease
and the levels of autoantibodies correlate with the progression and
recurrence free survival of the patients.
Circulating levels of Ma2 autoantibodies did not seem to reflect
the tumor mass per se as circulating levels for patients with lymph
node or liver metastases with higher tumor load did not show
significantly higher levels of autoantibodies. This supports the
notion that Ma2 autoantibodies appear early during SI-NET
development. These data pave the way for the possibility of using
Ma2 Autoantibodies and Carcinoids
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progression of SI-NETs growth. Furthermore, the identification of
Ma2 as a target of the autoimmune response in patients with SI-
NET may provide the first insights into the molecular mechanisms
of paraneoplastic syndrome in patients with these tumors. We also
presented preliminary results dealing with TLC and ALC. All
blood and tumor samples of lung carcinoids tested so far by ELISA
and immunohistochemistry on paraffin sections showed increased
expression of Ma2 in comparison with normal internal tissues.
This supports the view that Ma2 protein accumulation and the
presence of Ma2 autoantibodies is closely associated with the
development of several types of differentiated NETs.
Our study shows that lower titer of Ma2 autoantibodies
correlates to a lower probability of recurrence with longer survival
of SI-NET patients. This finding contradicts those reported in
other studies, for instance Graus et al. detected autoantibodies,
denoted anti-Hu antibodies, which recognize antigens expressed
by neurons, in small-cell lung carcinoma that have been associated
to patients’ longer survival [27]. Pujol et al. reported the presence
of autoantibodies and spontaneous complete remission of a non-
small cell lung cancer (SCLC) patient associated with anti-Hu
syndrome. Moreover, like Graus et al, they concluded that the
anti-Hu humoral immunology is associated to a positive tumor
response [28]. However, a more recent study reported that
onconeural antibodies, such as anti-Hu and anti-CV2/CRMP5
have a different behavior in different tumor types. Therefore, the
prognosis of the same type of tumor may differ according to the
type of analyzed onconeural antibodies [29].
The human immune system normally produces antibodies in
response to foreign proteins, such those of pathogens, and ignores
the body’s own cells proteins to avoid to trigger disease. When
the immune system fails to discriminate self from non-self, pro-
teins start producing antibodies against self proteins denoted
autoantibodies. A variety of theories have tried to explain why
Figure 4. A novel indirect ELISA detects Ma2 autoantibodies in lung carcinoid patients. Healthy controls (HC, n=50), untreated TLC
(n=52) and ALC patients (n=14) were evaluated for the presence of Ma2 autoantibodies. Horizontal bars in bold indicate the medians in each group.
Horizontal lines indicate the cutoff at 1900 AU (1.96 SD above control mean). 4A) p-values between healthy controls and the two groups of patients,
TLC and ALC show significant differences. 4B) p-values between healthy controls and all lung carcinoids (TLC + ALC) show significant differences. ROC
curve analyses and AUCs are shown in Figure 4C, 4D and 4E. The highlighted points in each graph indicate the cutoff.
doi:10.1371/journal.pone.0016010.g004
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why humoral autoimmunity can cause diseases is not fully
understood.
We detected Ma2 autoantibodies in the serum of SI-NET
patients. However, PNS was not correlated to the analyzed SI-
NET patients in this study. Although our conclusions differ from
those from other groups, we speculate that the presence of high
serum titer of Ma2 autoantibodies may predict poor prognosis in
patients suffering from SI-NETs, as previously shown in different
diseases. For instance, a significant study has evaluated autoan-
tibodies against insulin and beta-islet cells in pancreatic adeno-
carcinoma. Conclusive data suggested that the high serum titer of
both autoantibodies were associated with a worse outcome for the
patients [30]. A second study evaluated several serum antibodies
from colon cancer patients to isolate a novel cancer biomarker.
The new isolated biomarker was aberrantly expressed and the
level of serum autoantibodies was significantly higher in the
patients than in matched non cancerous tissue in healthy donors.
The authors of this study concluded that the detection of serum
antibody to tumor antigens might be a better marker than serum
antigens [31]. A third study has also showed that autoantibodies
predict poor prognosis in patients with advanced esophageal
squamous cell carcinoma [32].
Despite different reported findings we believe that the
description of the relationship between the presence of Ma2
autoantibodies and progression/recurrence free survival in SI-
NET offers new insights into the pathophysiology of this
malignancy. Furthermore, we have also shown that the patient
serum with high titer of Ma2 autoantibodies clearly detects Ma2 in
the neuroendocrine tumor cells and neurons of the Auerbach’s
plexus (or myenteric plexus). The novel finding suggests exploring
the potential role of anti-Ma2 in gut dysmotility via autoimmune-
mediated neuronal apoptosis and the recent detection of anti-Ma1
antibodies is opening a new window to evaluate autoimmunity in
the pathophysiology of these malignancies.
However, in conclusion we examined the performance
characteristics of a novel ELISA to detect Ma2 autoantibodies in
blood of SI-NET patients by measuring the sensitivity and
specificity capacity in discriminating patients from healthy
individuals. Furthermore, the presence of Ma2 autoantibodies is
an earlier and more sensitive circulating marker than CgA for the
risk of recurrence of the disease. To our knowledge this is the first
novel NET biomarker after many years to be evaluated for
diagnosis and risk of early recurrence after operation of primary
SI-NET tumors with a curative intent.
Materials and Methods
Ethics Statement
All patient and control blood samples were included in the study
after a written consent statement was obtained from each
individual. The study was performed in accordance with the
regional ethical committee at the Clinic of Endocrine Oncology,
Uppsala University Hospital, Sweden (ref. no. 2005:241) and the
internal revision board (IRB) of the European Institute of Onco-
logy, Milan, Italy.
Serum and plasma sample collection
Serum and plasma samples were obtained and analyzed from
124 patients with histopathology confirmed diagnosis of SI-NET:
36 with primary tumors, 38 with lymph node metastasis and 50
with liver metastasis. Patients with primary SI-NETs were
collected after surgery with a curative intent. Serum and plasma
samples were obtained and analyzed from 66 lung carcinoid
patients: 52 TC (named TLC) and 14 AC (named ALC). The
median ages of the patients were SI-NET 63 years (range, 27–82)
and TLC & ALC 59 years (range, 13–81). Moreover, 50 serum
samples from healthy volunteers were collected at the Uppsala
University Hospital and used as negative controls. Clinicians at the
Uppsala University Hospital, Neuroendocrine Center of Excel-
lence, Uppsala, Sweden and at the European Institute of
Oncology, Milan, Italy that follow the SI-NET and lung carcinoid
patients have never identified PNS and neurological symptoms.
Reagents and antibodies
Maxisorp strips (NunC, Roskilde, Denmark), GST-PNMA2
recombinant protein (Abnova, Taipei, Taiwan); 3,39,5,5-tetra-
methylbenzidine (TMB) + substrate (Dako, Glostrup, Denmark),
Peroxidase with dakocytomation peroxidase block (Dako), Dako-
cytomation envisionH system labeled polymer-HRP anti-rabbit kit
and 3-39-diaminobenzidine (Dako), Mayer’s hematoxylin (Histolab
Product AB, Gothenburg, Sweden), Graded alcohol (Kemetyl,
Vestby, Norway), Xylen (Solveco, Rosersberg, Sweden), PertexH
(Histolab, Gothenburg, Sweden), Tris-Glycine blotting buffer
(Amresco, Solon, OH), Western blotting (WB) reagent and
Lumi-Light WB substrate (Roche, Basel, Switzerland), EasyTag
Methionine-L-
35S, NEG709A005MC (PerkinElmer, Waltham,
MA), Full-length cDNA clone for human PNMA2, ID6580976
(BioScience Geneservice, Cambridge, UK), TnTH SP6 Quick
Coupled Transcription/Translation System (Promega, Madison,
WI), Protein G-Sepharose beads (GE Healthcare, Little Chalfont,
Buckinghamshire, UK), Peroxidase (HRP)-conjugated rabbit anti
human IgG (anti-IgG) (Dako), rabbit polyclonal antibody anti-
PNMA2 (Atlas Antibodies, Stockholm, Sweden), monoclonal
mouse anti-GST, sc-138, polyclonal goat anti-human Ma2, sc-
68099, HRP-donkey anti-goat, sc-2020, (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA), HRP-goat anti-rabbit, P0448, (Dako) and
Ravo PNS-Blot, (Ravo Diagnostika GmbH, Freiburg, Germany).
Indirect ELISA
We set up a novel indirect ELISA to detect Ma2 autoantibody
levels in sera and plasma of NET patients and healthy volunteers.
The standard curves to screen both serum and plasma samples
were constructed by serial dilutions 1:100, 1:200, 1:400, 1:800,
1:1,600, 1:3,200 and 1:6,400 using the serum and the plasma from
the same patient with primary SI-NET, expressing anti-Ma2 used
as reference. Two controls were used to evaluate individual runs.
One was from a patient with primary SI-NET, expressing high
titer of anti-Ma2 and the other one was from a healthy donor
expressing low titer of anti-Ma2. GST-PNMA2 recombinant
protein (Abnova, Taiwan), diluted in the coating buffer (15 mM
Na2CO3, 35 mM NaHCO3, pH 9.6), at the concentration of
1 mg/ml was used to coat Maxisorp strips with 50 ml each well for
17 hours at 4uC. Strips were washed 3 times with washing buffer
(PBS pH 7.4, 0.05% Tween-20). Strips were blocked with 200 ml
of blocking buffer (PBS pH 7.4, 0.05% Tween-20 and 5% BSA)
for 2 hours at room temperature. Strips were washed 3 times.
Serum and plasma samples were diluted 1:400 in PBS pH 7.4,
0.05% Tween-20, 1% BSA and loaded into wells. The samples
were run in duplicates. They were incubated for 2 hours at room
temperature. Strips were washed 6 times. Next, 50 ml of HRP-
conjugated rabbit anti human IgG (1:500) was added and
incubated for 1 hour at room temperature. Strips were washed 8
times and then incubated with 100 ml TMB substrate for 30 min.
Reaction was stopped with 100 ml of 1M H2SO4. Absorbance was
read by Multiskan Ascent microplates photometer (Thermo Fisher
Scientific, Waltham, MA) by using Ascent software version 2.6
(Thermo Elelectron corporation, Waltham, MA). Blank absor-
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curve was plotted. Serum and plasma reference samples were
arbitrarily defined as 3200 arbitrary units (AU) for the standard
curve and the results were expressed as concentrations according
to the standard curve. The cut-off at 1900 AU (arbitrary unit) was
chosen as 1.96 SD above the mean anti-Ma2 concentration of the
healthy control group. Experiments were repeated two times. The
precision of ELISA is expressed in intra- and inter-assay percent
coefficient of variation (CV%). The intra-assay CV% between
each duplicate is below 10%, a value that is considered to be
reliable. The inter-assay CV% is 9.4% for the higher control and
8.9% for the lower control.
Statistical Analysis
The power and sample size calculations were performed by using
R.V. Lenth’s Java applets for power and sample size [33]. The
nonparametric Mann-Whitney U test [34] was used to assess the
statistical significance of the anti-Ma2 concentration difference
between the healthy controls and the different patient groups. The
ROC curves provide a display of the relationships between the true
positive rates (sensitivities) and false positive rates (1 2 specificities)
relatedto all binary tests forthe biomarker.Theshapes ofthecurves
and AUCs presented with corresponding 95% confidence intervals
(CI) are used to discriminate the diagnostic accuracies between tests
[35]. The ROC curves were in this study generated to compare the
AUCs and the predicted sensitivities and specificities among
different NETs and different stages of disease. The statistical
analyses were two-tailed and performed by usingGraphPad Prism 5
(GraphPad Software, La Jolla, CA). We also computed Kaplan-
Meier estimates for PFS and RFS [36] for two groups of patients
based on the anti-Ma2 cutoff, as described above. Kaplan-Meier
curves were compared by means of the log-rank test. The hazard
ratio in survival analysis is the effect of an explanatory variable on
the hazard or risk of an event, and such models include the Cox
semi-parametric proportional hazards model. The hazard ratios for
patients based on the diverse groups were calculated by Cox’s
regression method. Cox regression is a statistical technique that is
used to determine the relationship between survival and several
independent variables. This function provides better estimates of
survival probabilities and cumulative hazard than those provided by
the Kaplan-Meier function. We used a multivariate Cox propor-
tional-hazards regression modeling to evaluate the effect of Ma2
autoantibody titer and CgA concentration on PFS and RFS of our
patients [37]. Survival data were computed by using the survival
package in R software. All p values ,0.05 were considered
significant.
Immunohistochemistry
Formalin-fixed paraffin-embedded material with histopatholog-
ically confirmed diagnosis of metastasized SI-NETs and lung
carcinoids were obtained as 3-mm-thick sections from the
Pathology Biobank, Uppsala University Hospital and the Euro-
pean Institute of Oncology, Milan, Italy. We selected tumor
material from 20 untreated SI-NET patients at different stage of
disease with primary tumors (P), lymph node metastases (LNM)
and liver metastases (LM). Tumor samples matched with blood
samples used for ELISA. We selected both primary tumors and
metastases from 14 lung carcinoid patients, 10 with TLC (1 man
and 9 women) and 4 with ALC (3 men and 1 woman). Slides were
deparaffinized in xylene, hydrated in graded alcohols and blocked
for endogenous peroxidase with dakocytomation peroxidase block
(Dako). For antigen retrieval slides were immersed in 10 mM
citrate buffer, pH 6 and then boiled in microwave. Sections were
stained with the primary rabbit polyclonal antibody anti-PNMA2
(Atlas Antibodies), diluted 1:350 at 4uC overnight (O.N.). The day
after, they were incubated with a secondary antibody by using
HRP anti-rabbit kit (Dako), according to the manufacturers’
instructions. Peroxidase activity was developed with 3-39-diami-
nobenzidine (Dako). Sections were then counterstained in Mayer’s
hematoxylin (Histolab Product AB), dehydrated in graded alcohol
and xylen and mounted by using Pertex (Histolab). The specificity
of all immunoreactions was double-checked by substituting the
primary antibody with a non-related polyclonal antibody at a
comparable dilution, and with normal serum alone. Furthermore,
serum from SI-NET patient and healthy control were used to stain
Ma2 on five SI-NET tissue slides. The slides were blocked with
peroxidase and then with 10% of normal rabbit serum for 30 min.
Serum from one SI-NET patient with high titer of anti-Ma2 and
from one healthy donor with low titer of anti-Ma2 were diluted
1:100 in PBS and used to immunostain the slides at 4uC, O.N.
After proper washing, HRP-conjugated rabbit anti-human IgG
(1:500, Dako) was applied for 30 min on the slides. Peroxidase
activity was measured as described above.
Western Blot Analysis
GST-tagged PNMA2 recombinant protein (Abnova) (440 ng in
2 ml) were mixed with an equal volume of 4X loading buffer
(200 mM pH 6.8 Tris-HCl, 8% sodium dodecyl sulfate, 40%
glycerol and 0.1% bromophenol blue) and 5% b-mercaptoethanol.
The samples were heated at 95uC, loaded and run on a 10%
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE). The proteins were then blotted onto a nitrocellulose
membrane in Tris-Glycine blotting buffer (Amresco) with
methanol at 100 V for 2 hours at 4uC. After blotting the
membrane was stained with Pouceau S to verify protein transfer.
The membrane was cut in eight strips. The strips were blocked
with TBS, 1% western blotting reagent (Roche) at 4uC, O.N. Each
strip was then incubated at 4uC, O.N. with either a commercial
antibody or a serum sample diluted in dilution buffer (TBS, 0.5%
western blotting reagent and 0.02% sodium azide). We used
monoclonal mouse anti-GST, sc-138, (Santa Cruz), diluted 1:500
and polyclonal goat anti-human Ma2, sc-68099 (Santa Cruz),
diluted 1:1000 as positive controls. The polyclonal goat anti-
human antibody specifically recognizes Ma2 and cannot detect
Ma1. We used serum samples from two healthy donors with Ma2
autoantibody titer below cutoff (1900 AU), from two patients with
primary SI-NET expressing Ma2 autoantibodies below cutoff and
two patients with primary SI-NET expressing Ma2 autoantibodies
at higher titer than cutoff. All the serum samples were diluted 1:50.
After the incubation, each strip was washed with TBS, 0.1%
Tween-20 and incubated with secondary antibodies HRP-rabbit
anti-mouse, P0161, diluted 1:5000, HRP-donkey anti-goat, sc-
2020, diluted 1:5000, and HRP-rabbit anti-human IgG, P0214,
diluted 1:3000. The strips were then washed, incubated 10 seconds
with Lumi-Light Western Blotting Substrate (Roche) and exposed
in a Biorad Chemidoc XRS System (Bio-Rad Laboratories,
Hercules, CA). The image was elaborated by using Quantity One
software.
In vitro transcription-coupled translation and sequential
immunoprecipitation
35S Met–radiolabeled human PNMA2 protein was produced by
in vitro transcription coupled translation from the full-length cDNA
clone for human PNMA2 (BioScience Geneservice) by using
35S-
methionine and TnTH SP6 Quick Coupled Transcription/
Translation System (Promega), according to manufacturer’s
instructions. During sequential immunoprecipitation two indepen-
dent immunoprecipitations were performed. Briefly, in the first
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counts per minute (CPM)
35S-labeled PNMA2. Positive and
negative controls were incubated with or without 0.5 mgo f
commercial polyclonal goat anti-human PNMA2. The final
volume of each reaction was 50 ml by using the IP buffer
(50 mmol/l NaCl, 20 mmol/l pH 7.4 Tris-HCl, 0.02% sodium
azide, 0.1% BSA and 0.15% Tween-20) used both for washing
and dilution steps. Incubation was performed at 4uC O.N. The
day after 50 ml of protein G-Sepharose beads (GE Lifescience)
were incubated to each sample. After incubation at 4uC for
2 hours the samples were centrifuged at 380 g, the beads were
collected and the supernatants were removed. The beads were
washed 5 times, by using IP buffer and centrifugations. Then,
50 ml of IP buffer was added to each sample. The beads were then
heated at 80uC for 5 minutes and the proteins were released. After
centrifugation the supernatants were collected. For the second
immunoprecipitation 0.6 mg of goat anti-human Ma2 antibody,
previously used in the western blot analysis, was added to the new
samples and incubated at 4uC, O.N. Thereafter, we added 50 ml
protein G-Sepharose beads to each sample and continued the
incubation at 4uC for 2 hours. The samples were centrifuged at
380 g, and washed 5 times with IP buffer to collect the beads. They
were resuspended in 40 ml of SDS-PAGE 4X loading buffer
containing 5% b-mercaptoethanol. The immunocomplexes,
containing
35S-labeled PNMA2 protein, were released and
denatured from the beads by heating at 95uC for 5 minutes.
After centrifugation 20 ml of each sample were resolved by 10%
SDS-PAGE. The gel was dried, subjected to autoradiography, by
using phosphoimager 425S (Molecular Dynamics, Sunnyvale, CA)
and analyzed by using ImageQuant software.
Immuno-(Dot)-Blot for the detection of the anti-Ma2 and
anti-Ma1
Recombinant immunoblot was used to detect the anti-Ma2 and
anti-Ma1 antibodies. We used the available strips, spotted with the
recombinant proteins. RAVO reagents were used for staining the
recombinant proteins in the positive control strip according to the
manufacturer’s instruction. We also used 5 different strips for
evaluating commercial antibodies and patient sera by using the
method described above in Material & Methods (Western Blot
Analysis) to use the same reagents and protocols to evaluate both
commercial antibodies and sera. We used rabbit anti-PNMA2
(Atlas Antibodies) and goat anti-human Ma2 (SantaCruz) 1:1000
to verify the specificity of these commercial antibodies. Serum
samples from one healthy donor with low titer of anti-Ma2
and one serum sample from one patient with high titer of
anti-Ma2. Serum samples were diluted 1:10. Primary Antibodies
and serum samples were incubated at 4uC over night. We used
HRP-goat anti-rabbit (1:3000, Dako), HRP-donkey anti-goat
(1:3000, SantaCruz) and HRP-rabbit anti-human IgG (1:3000,
Dako) as secondary antibodies. The strips were then washed,
incubated 10 s with Lumi-Light Western Blotting Substrate
(Roche) and exposed in a Biorad Chemidoc XRS System (Bio-
Rad Laboratories, Hercules, CA), as described in Western Blot
Analysis.
Supporting Information
Figure S1 Immuno-(dot)-blot used to detect anti-Ma2
and anti-Ma1. Positive control (lane 1), Negative control (lane
2), Goat anti-Ma2 antibody specifically detects Ma2 (lane 3),
Rabbit anti-Ma2 antibody specifically detects Ma2 (lane 4), Serum
from healthy donor fails to detect Ma2 (lane 5) whereas Serum
from one SI-NET patient with high titer of Ma2 autoantibodies
detects Ma2 and faintly Ma1 (lane 6). Reaction control evaluates
the performance of the blot.
(TIF)
Figure S2 Immunostaining of Ma2 on specimens from
untreated SI-NET patients matched with blood samples.
12 patients out of 12 expressing high titer of Ma2 autoantibodies,
as described in Table S1, were positively stained. Eight patients
with low titer of Ma2 autoantibodies, as described in Table S1,
showed that 7 out of 8 specimens were positively stained while one
was negative. Figure S2 shows four representative staining from
patients with high titer of Ma2 autoantibodies, panel A and with
low titer of Ma2 autoantibodies, panel B. Bar =50 mm.
(TIF)
Figure S3 Serum from primary SI-NET patients with
high anti-Ma2 titer efficiently immunostain tumor
cells and neurons on tissue sections from primary SI-
NETs. We stained paraffin embedded tissue sections from
untreated primary SI-NET patients, by using serum from a
primary SI-NET patient with high anti-Ma2 titer and serum from
a healthy donor. One representative Ma2 staining is shown. In
upper panels, on the left tumor cells and on the right neurons,
located in the Auerbach’s plexus (or myenteric plexus) are Ma2
stained. In lower panels, serum from healthy donor faintly stains
Ma2. Tumor cells are shown on the left and neurons on the right.
Bar =50 mm.
(TIF)
Figure S4 Ma2 Immunoreactivity in lung carcinoids.
The mean of Ma2-positive tumor cells in typical carcinoids is 54%
and in atypical carcinoids is 28%, independent of tumor growth
patterns of the former. Typical carcinoids exhibited either diffuse
positivity of tumor cells in trabecular growing tumors A and as an
inset A-bis or heterogeneous distribution of the signal in spindle
cell tumors or spindle cell component of tumors B. Atypical
carcinoids presented with heterogeneous distribution of the
immunostaining product inside tumor cells with intermingling of
negative and faint to moderate reactivity C or completely negative
tumor cells D. Bar =50 mm.
(TIF)
Table S1 Circulating Ma2 autoantibody levels in serum samples
and cytoplasmic Ma2 expressions in paraffin-embedded tissues of
20 SI-NET patients.
(DOC)
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